PLUS THERAPEUTICS, Inc. Common Stock (PSTV)
Plus Therapeutics, Inc. (PSTV) is a clinical-stage biopharmaceutical company focused on developing targeted radiopharmaceuticals for the treatment of cancer. The company aims to leverage novel radioisotope-based therapies to improve outcomes for patients with difficult-to-treat tumors, utilizing advanced delivery platforms to enhance efficacy and minimize side effects.
Company News
The leptomeningeal metastases market is projected to grow slowly due to rising cancer incidence and increasing central nervous system complications. Several emerging therapies like REYOBIQ and Paxalisib are expected to drive market development in the coming years.
DURECT (DRRX) delivered earnings and revenue surprises of 25% and 1.19%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
The Dow Jones closed lower by around 40 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Plus Therapeutics The Trade: Plus Therapeutics, Inc. (NASDAQ: PSTV) Director Robert Lenk acquired a total of 7,395 shares an average price of $1.61. To acquire these shares, it cost around $11,933. What’s Happening: Plus Therapeutics ...
Are these penny stocks to watch on your list this week? The post Penny Stocks To Buy Now? 4 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.